Marker vaccine for classical swine fever
AssigneeIdt Biologika GmbH
InventorsMartin Beer, Sandra Blome, Immanuel Leifer
Life of this patent
Estimating the term…
Abstract
The invention relates to a marker vaccine for prophylactic treatment of classical swine fever comprising modified live attenuated classical swine fever virus. The viral amino acid sequence of the TAV-epitope of the E2 protein comprises a different sequence from that of a wild-type classical swine fever virus. The invention relates to pharmaceutical compositions of the marker vaccine. The invention also relates to a method of manufacturing marker vaccines for prevention of classical swine fever using selective antibody pressure.
Claims14
A marker vaccine for prophylactic treatment of classical swine fever comprising:
- a modified live attenuated classical swine fever virus having an E2 protein comprising a viral amino acid sequence of a TAV-epitope, wherein said viral amino acid sequence of the TAV-epitope of the E2 protein comprises a sequence that differs from that of a wild-type classical swine fever virus, wherein the viral amino acid sequence comprises at least one of the following substitutions with reference to a numbering of the viral amino acid sequence of a C-strain “Riems” virus:
- substitution of amino acid 830 to valine,
- substitution of amino acid 839 to glycine.
Dependencies are inferred from the claim text.